Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.

Guidez S, Labreuche J, Drumez E, Ysebaert L, Bakala J, Delette C, Hivert B, Protin C, Declercq H, Verlay M, Marolleau JP, Duhamel A, Morel P; French Innovative Leukemia Organization (FILO) CLL group.

Blood Adv. 2018 Nov 27;2(22):3102-3111. doi: 10.1182/bloodadvances.2018021287.

2.

Dose-limiting stomatitis associated with ibrutinib therapy: a case series.

Vigarios E, Beylot-Barry M, Jegou MH, Oberic L, Ysebaert L, Sibaud V.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15620. [Epub ahead of print] No abstract available.

PMID:
30408164
3.

[Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].

Gauthier M, Comont T, Vergez F, Ysebaert L.

Bull Cancer. 2018 Nov;105(11):1042-1051. doi: 10.1016/j.bulcan.2018.07.008. Epub 2018 Sep 20. Review. French.

PMID:
30243477
4.

Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.

Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V; FILO working group.

Genes Chromosomes Cancer. 2018 Nov;57(11):533-540. doi: 10.1002/gcc.22650. Epub 2018 Sep 11.

PMID:
30203893
5.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.

N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.

PMID:
30184451
6.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

7.

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H.

Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154. [Epub ahead of print]

PMID:
29884994
8.

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.

Grgurevic S, Montilla-Perez P, Bradbury A, Gilhodes J, Queille S, Pelofy S, Bancaud A, Filleron T, Ysebaert L, Récher C, Laurent G, Fournié JJ, Cazaux C, Quillet-Mary A, Hoffmann JS.

Haematologica. 2018 Jun;103(6):1038-1046. doi: 10.3324/haematol.2017.174243. Epub 2018 Mar 22.

9.

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L; French Innovative Leukemia Organization (FILO) CLL group.

Blood. 2018 Apr 26;131(17):1955-1959. doi: 10.1182/blood-2017-11-818286. Epub 2018 Feb 1.

PMID:
29437588
10.

Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.

Ribes D, Hachem HEL, Oberic L, Vergez F, Delas A, Belliere J, Protin C, Kamar N, Ferrandiz I, Tavitian S, Laurent C, Huart A, Chauveau D, Ysebaert L, Faguer S.

Am J Hematol. 2018 Mar;93(3):356-362. doi: 10.1002/ajh.24984. Epub 2017 Dec 6.

PMID:
29168251
11.

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).

Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A.

Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. No abstract available.

PMID:
29164674
12.

Nurse-like cells promote CLL survival through LFA-3/CD2 interactions.

Boissard F, Tosolini M, Ligat L, Quillet-Mary A, Lopez F, Fournié JJ, Ysebaert L, Poupot M.

Oncotarget. 2016 Nov 26;8(32):52225-52236. doi: 10.18632/oncotarget.13660. eCollection 2017 Aug 8.

13.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.

Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12.

14.

Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia.

Bétrian S, Guenounou S, Luquet I, Demur C, Huynh A, Ysebaert L, Recher C, Huguet F.

Hematol Oncol. 2017 Jun;35(2):252-255. doi: 10.1002/hon.2252. Epub 2015 Oct 8.

PMID:
28620927
15.

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.

Ysebaert L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J, Sinet P, Albrecht C, Cymbalista F.

Am J Hematol. 2017 Aug;92(8):E166-E168. doi: 10.1002/ajh.24773. Epub 2017 May 30. No abstract available.

16.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29. No abstract available.

17.

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F.

Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7.

18.

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C.

Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4.

PMID:
28257752
19.

[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].

Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N.

Bull Cancer. 2017 Mar;104(3):221-231. doi: 10.1016/j.bulcan.2017.01.007. Epub 2017 Feb 15. French.

PMID:
28214006
20.

Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis.

Ribes D, Casemayou A, El Hachem H, Laurent C, Guilbeau-Frugier C, Vergez F, Tavitian S, Schanstra JP, Chauveau D, Bascands JL, Ysebaert L, Faguer S.

Clin Exp Nephrol. 2017 Oct;21(5):781-786. doi: 10.1007/s10157-016-1373-6. Epub 2016 Dec 26.

PMID:
28018996
21.

Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement.

Gravelle P, Do C, Franchet C, Mueller S, Oberic L, Ysebaert L, Larocca LM, Hohaus S, Calmels MN, Frenois FX, Kridel R, Gascoyne RD, Laurent G, Brousset P, Valitutti S, Laurent C.

Oncoimmunology. 2016 Aug 24;5(10):e1224044. eCollection 2016.

22.

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P.

Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22.

PMID:
27878835
23.

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.

Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, Lepretre S, Re D, Fahri J, Michallet AS, Ysebaert L, Lemal R, Lamy T, Delarue R, Troussard X, Cymbalista F, Levy V, Dietrich PY, Leblond V, Aurran-Schleinitz T.

Br J Haematol. 2017 Jan;176(1):37-49. doi: 10.1111/bjh.14387. Epub 2016 Nov 11.

PMID:
27858991
24.

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C.

Oncotarget. 2016 Dec 27;7(52):85937-85947. doi: 10.18632/oncotarget.13262.

25.

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Betrian S, Ysebaert L, Heider KH, Delord JP, Fournié JJ, Quillet-Mary A.

Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106. No abstract available.

26.

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.

Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, Österborg A, Poddubnaya I, Woyach JA, Shanafelt T, Smolej L, Ysebaert L, Goede V.

Ann Oncol. 2017 Feb 1;28(2):218-227. doi: 10.1093/annonc/mdw547.

PMID:
27803007
27.

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F.

Br J Haematol. 2016 Nov;175(3):462-466. doi: 10.1111/bjh.14324. Epub 2016 Sep 9.

PMID:
27611233
28.

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.

Clin Pharmacokinet. 2017 Jun;56(6):635-647. doi: 10.1007/s40262-016-0470-8.

PMID:
27783363
29.

Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.

Alric L, Besson C, Lapidus N, Jeannel J, Michot JM, Cacoub P, Canioni D, Pol S, Davi F, Rabiega P, Ysebaert L, Bonnet D, Hermine O.

PLoS One. 2016 Oct 17;11(10):e0162965. doi: 10.1371/journal.pone.0162965. eCollection 2016.

30.

Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.

Le Bris Y, Struski S, Guièze R, Rouvellat C, Prade N, Troussard X, Tournilhac O, Béné MC, Delabesse E, Ysebaert L.

Hematol Oncol. 2017 Dec;35(4):664-670. doi: 10.1002/hon.2349. Epub 2016 Sep 28.

PMID:
27678008
31.

3R gene expression in chronic lymphocytic leukemia reveals insight into disease evolution.

Grgurevic S, Berquet L, Quillet-Mary A, Laurent G, Récher C, Ysebaert L, Cazaux C, Hoffmann JS.

Blood Cancer J. 2016 Jun 3;6(6):e429. doi: 10.1038/bcj.2016.39. No abstract available.

32.

Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets.

Levade M, Severin S, Gratacap MP, Ysebaert L, Payrastre B.

Curr Pharm Des. 2016;22(16):2315-22. Review.

PMID:
26916020
33.

Nurse-like cells impact on disease progression in chronic lymphocytic leukemia.

Boissard F, Laurent C, Ramsay AG, Quillet-Mary A, Fournié JJ, Poupot M, Ysebaert L.

Blood Cancer J. 2016 Jan 15;6:e381. doi: 10.1038/bcj.2015.108. No abstract available.

34.

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.

Ysebaert L, Laprévotte E, Klein C, Quillet-Mary A.

Blood Cancer J. 2015 Nov 13;5:e367. doi: 10.1038/bcj.2015.93. No abstract available.

35.

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.

Boissard F, Fournié JJ, Quillet-Mary A, Ysebaert L, Poupot M.

Blood Cancer J. 2015 Oct 2;5:e355. doi: 10.1038/bcj.2015.74. No abstract available.

36.

Several immune escape patterns in non-Hodgkin's lymphomas.

Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, Brousset P, Bidaut A, Ycart B, Fournié JJ.

Oncoimmunology. 2015 Apr 2;4(8):e1026530. eCollection 2015 Aug.

37.

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Guièze R, Robbe P, Clifford R, de Guibert S, Pereira B, Timbs A, Dilhuydy MS, Cabes M, Ysebaert L, Burns A, Nguyen-Khac F, Davi F, Véronèse L, Combes P, Le Garff-Tavernier M, Leblond V, Merle-Béral H, Alsolami R, Hamblin A, Mason J, Pettitt A, Hillmen P, Taylor J, Knight SJ, Tournilhac O, Schuh A.

Blood. 2015 Oct 29;126(18):2110-7. doi: 10.1182/blood-2015-05-647578. Epub 2015 Aug 27.

38.

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies.

Tavitian S, Peron JM, Huguet F, Kamar N, Abravanel F, Beyne-Rauzy O, Oberic L, Faguer S, Alric L, Roussel M, Gaudin C, Ysebaert L, Huynh A, Recher C.

Emerg Infect Dis. 2015 Aug;21(8):1466-9. doi: 10.3201/eid2108.150199.

39.

L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo.

Lafouresse F, Bellard E, Laurent C, Moussion C, Fournié JJ, Ysebaert L, Girard JP.

Blood. 2015 Sep 10;126(11):1336-45. doi: 10.1182/blood-2015-02-626291. Epub 2015 Jul 10.

40.

Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.

Ysebaert L, Feugier P, Michallet AS.

Curr Opin Oncol. 2015 Sep;27(5):365-70. doi: 10.1097/CCO.0000000000000213. Review.

PMID:
26154708
41.

Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia.

Berquet L, Valleron W, Grgurevic S, Quelen C, Zaki O, Quillet-Mary A, Davi F, Brousset P, Bousquet M, Ysebaert L.

Br J Haematol. 2016 Mar;172(5):819-23. doi: 10.1111/bjh.13544. Epub 2015 Jun 11. No abstract available.

PMID:
26095450
42.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.

Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L.

Am J Hematol. 2015 Jun;90(6):511-4. doi: 10.1002/ajh.23999. Epub 2015 Apr 1.

43.

Acquired epidermodysplasia verruciformis, a new opportunistic infection related to bendamustine.

Cougoul P, Tournier E, Delavigne K, Rauzy OB, Ysebaert L, Sibaud V.

Ann Hematol. 2015 Jun;94(6):1071-3. doi: 10.1007/s00277-015-2329-8. Epub 2015 Feb 14. No abstract available.

PMID:
25677268
44.

Nurse like cells: chronic lymphocytic leukemia associated macrophages.

Boissard F, Fournié JJ, Laurent C, Poupot M, Ysebaert L.

Leuk Lymphoma. 2015 May;56(5):1570-2. doi: 10.3109/10428194.2014.991731. Epub 2015 Feb 11.

PMID:
25586606
45.

Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Dartigeas C, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Apr 14;5:10. doi: 10.1186/s40164-016-0038-1. eCollection 2015.

46.

New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Mar 1;5:7. doi: 10.1186/s40164-016-0036-3. eCollection 2015. Erratum in: Exp Hematol Oncol. 2015;5:10.

47.

Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).

Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, Michallet AS, Feugier P, Guieze R, Levy V, Delmer A.

Am J Hematol. 2015 Mar;90(3):204-7. doi: 10.1002/ajh.23909. Epub 2015 Jan 16.

48.

Bendamustine is effective in T-cell prolymphocytic leukaemia.

Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L.

Br J Haematol. 2015 Mar;168(6):916-9. doi: 10.1111/bjh.13175. Epub 2014 Oct 15. No abstract available.

PMID:
25316212
49.

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sié P, Ysebaert L, Payrastre B.

Blood. 2014 Dec 18;124(26):3991-5. doi: 10.1182/blood-2014-06-583294. Epub 2014 Oct 10.

50.

PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma.

Alcantara M, Dupuis J, Mareschal S, Julian A, Cottereau AS, Becker S, Dubois S, Oberic L, Huynh A, Meignan M, Laurent G, Tilly H, Haioun C, Ysebaert L.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):215-21. doi: 10.1007/s00259-014-2896-2. Epub 2014 Sep 20.

PMID:
25239490

Supplemental Content

Loading ...
Support Center